• AAPL 169.02
  • TSLA 162.13
  • AMZN 176.59
  • MSFT 409.06
  • INTC 34.5
  • EURUSD 1.0728
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. JK /
  3. APLN.JK

Agung Podomoro Land Tbk (APLN JK) stock market data APIs

Rp111 0(0%) as of April 25, 2024

Agung Podomoro Land Tbk Financial Data Overview

111
111
-
112
110
110-175
2 542 322 M
2.348
22 699 M
4 676 652 M
-15.8922
1.096
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'APLN',
Type: 'Common Stock',
Name: 'Agung Podomoro Land Tbk',
Exchange: 'JK',
CurrencyCode: 'IDR',
CurrencyName: 'Indonesian Rupiah',
CurrencySymbol: 'Rp',
CountryName: 'Indonesia',
CountryISO: 'ID',
ISIN: 'ID1000117104',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Real Estate',
Industry: 'Real Estate - Development',
}

Agung Podomoro Land Tbk Fundamental Data is available in our Financial Data APIs

  • Net Revenue 4 676 652 M
  • EBITDA 1 432 089 M
  • Earnings Per Share 47.7
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Agung Podomoro Land Tbk Earnings via APIs

  • Latest Release 2023-06-29
  • EPS/Forecast NaN

Get Agung Podomoro Land Tbk End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Agung Podomoro Land Tbk latest news via APIs

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

Topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease in Phase 3 study ATI-1801 may be eligible for tropical disease priority review vouch...
  • APPILI THERAPEUTICS
  • BIOPHARMACEUTICAL COMPANY
  • CLINICAL STAGE
  • CUTANEOUS LEISHMANIASIS
  • DEVELOPMENT ACTIVITIES
  • DEVELOPMENT PIPELINE
  • DRUG DEVELOPMENT
  • SOCIOECONOMIC DEVELOPMENT
  • US ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY
  • US DEPARTMENT OF DEFENSE

Trxade Group to Present at March Investor Conferences

TAMPA, FL / ACCESSWIRE / March 5, 2021 / Trxade Group, Inc. (NASDAQ:MEDS), a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience, today announced...
  • HEALTH SERVICES
  • INC
  • INVESTOR CONFERENCES
  • MAXIM GROUP
  • SUREN AJJARAPU
  • TRXADE GROUP
  • VIRTUAL PRESENTATIONS
  • WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE
Do you have any questions?
support@eodhistoricaldata.com